Click Here for Additional Resources
John Mack, Publisher of Pharma Marketing News, interviews Pharmaguy™, "constructive critic" of the pharmaceutical industry, blogger, Twitter celebrity, and Chief Pundit at pharmaguy.com (see Bio), about his decision to "break away" from John Mack in order to focus his efforts on speaking at live events and webinars and to more fully engage with his many followers via social networks such as Twitter, Pharma Marketing Blog, Tumblr, Facebook, and Google+.
Recorded on: Tuesday, November 5, 2013
You can visit this Pharma Marketing Talk Segment Page and listen to the live show or the archived audio podcast afterward. This show and ALL Pharma Marketing Talk shows are available as podcasts via PMT on iTunes (FREE!).
For the past five years Pharmaguy and John Mack were joined at the hip as it were. Everywhere Pharmaguy went, he carried two business cards -- one as John Mack, Publisher of Pharma Marketing News and one as Pharmaguy, Pundit. It was confusing. Sometimes people would confuse Mack for Pharmaguy and vice versa.
"What has changed," says Pharmaguy, "is that I am now able to assert myself independent of you [Mack] because our long-term non-disclosure agreement has expired. Finally, I am able to reveal my true identity and put some distance between myself and John Mack; i.e., you."
- What was the relationship between you and John Mack for the past 5 years?
- Why are you going independent now?
- What activities will you focus on?
- What will your relationship with John Mack going forward?
Pharmaguy™ (@pharmaguy) is a "constructive critic" of the pharmaceutical industry, often writing insightful posts to Pharma Marketing Blog, which was created in 2005 by John Mack, publisher of Pharma Marketing News. Pharmaguy did not come into public view until 2008 when he started tweeting using the "pharmaguy" handle (@pharmaguy).
Pharmaguy is a rising celebrity in pharma Twitterdom and is often invited to speak at industry conferences, webinars, and within major pharmaceutical companies such as Novartis, Sanofi, Bayer, Roche, and Celgene.